...children and adults with recent-onset type 1 diabetes. In March, the anti-CD3 mAb otelixizumab from Tolerx Inc....
...plc failed in the Phase III DEFEND-1 trial in patients with new-onset type 1 diabetes. Tolerx...
...Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Tempero Pharmaceuticals Inc. , Cambridge, Mass. Tolerx Inc....

...Lilly and Co. 's teplizumab anti-CD3 mAb failed in a Phase II/III trial. In March, Tolerx Inc....
...Jolla Institute for Allergy & Immunology , La Jolla, Calif. MacroGenics Inc. , Rockville, Md. Tolerx Inc....

...Bioscience Inc. , Cambridge, Mass. Business: Neurology Hired: Thomas Shea as CFO, formerly CFO of Tolerx Inc. WIR...

...NASDAQ:TRGT) TC-5619 fails in a Phase II trial to treat ADHD in patients ages 18-65 Tolerx Inc./GlaxoSmithKline...

...clinical development program for the compound. In 2001, BTG granted worldwide rights for otelixizumab to Tolerx...
...develop and commercialize the product (see BioCentury, Oct. 29, 2007). BTG plc (LSE:BGC), London, U.K. Tolerx Inc....

...technology (see B13) . BTG plc (LSE:BGC) gained 1.90p to 217.60p on Friday even as Tolerx Inc....
...BTG, which was up 3.20p on the week, granted worldwide rights for otelixizumab to Tolerx...

...technology (see B13) . BTG plc (LSE:BGC) gained 1.90p to 217.60p on Friday even as Tolerx Inc....
...BTG, which was up 3.20p on the week, granted worldwide rights for otelixizumab to Tolerx...

...for rheumatoid arthritis (RA). In 2001, BTG plc (LSE:BGC) granted worldwide rights for otelixizumab to Tolerx...

...with no treatment. Next steps could include using the model to test other anti-CD3 antibodies. Tolerx Inc....

...melanoma. Data were presented at the Keystone Symposia on Antibodies as Drugs meeting in Keystone. Tolerx Inc....